Global Medical Manager | Abbott | Switzerland
Based on Marcelo Graziano Custodio’s extensive background and accomplishments, here’s an analysis for the Research for Visionary Research Impact Award:
Strengths for the Award:
- Leadership in Medical Affairs: Marcelo has held pivotal roles in leading medical teams across multiple pharmaceutical companies (Abbott, AstraZeneca, Merck Serono), demonstrating his ability to drive strategic initiatives and achieve significant milestones in therapeutic areas like Women’s Health, Onco-Hematology, and Oncology.
- Global Impact: His work spans international boundaries, contributing to global leadership in menopause treatment and reproductive health. Marcelo’s efforts in expanding geographical reach (Asia-Pacific, Latin America) highlight his strategic acumen and execution capabilities.
- Scientific Contributions: Marcelo has been involved in numerous scientific publications and presentations, focusing on topics ranging from ultra-low-dose hormone therapies to economic evaluations in oncology. His contributions to clinical research and real-world data generation underscore his commitment to advancing medical knowledge.
- Professional Recognition: Marcelo has received multiple internal awards at Abbott for scientific leadership, teamwork, and excellence in medical affairs. These accolades reflect his peers’ and leaders’ acknowledgment of his contributions and impact within the industry.
- Educational and Training Initiatives: He has developed continuous medical education programs in collaboration with global medical societies, emphasizing his dedication to advancing medical knowledge and training future medical professionals.
Areas for Improvement:
- Broader External Recognition: While Marcelo has received internal awards, external recognition through industry-wide awards or peer-reviewed publications could further enhance his profile and influence in the field.
- Diversification of Therapeutic Areas: While Marcelo has significant expertise in Women’s Health and Oncology, further expanding into other therapeutic areas could broaden his impact and relevance in the pharmaceutical industry.
- Public Engagement and Advocacy: Increasing visibility through speaking engagements, panel discussions, or thought leadership articles could amplify his influence on critical healthcare issues beyond the pharmaceutical sector.
Conclusion:
Marcelo Graziano Custodio is a highly accomplished medical affairs professional with a robust track record in pharmaceutical leadership, global medical initiatives, and scientific contributions. His strategic insights, combined with a commitment to advancing medical education and clinical research, make him a strong candidate for the Research for Visionary Research Impact Award. Enhancing external visibility and diversifying therapeutic expertise could further solidify his position as a leader in the global healthcare landscape.
Short Biography 🌟
Marcelo Graziano Custodio, MD TEGO MSc MBA, is a Brazilian-Italian medical professional with extensive expertise in pharmaceuticals, specializing in Oncology, Onco-Hematology, and Women’s Health. Currently serving as Global Women’s Health Medical Lead at Abbott, he has driven significant advancements in medical affairs and clinical research across multiple continents.
Profile
SCOPUS
Education 📚
Marcelo Graziano Custodio pursued his Medical Degree and subsequent residency in Gynecology & Obstetrics at the University of Sao Paulo, Brazil. He furthered his academic journey with an Expert certification from the Brazilian Federation of Gynecology and Obstetrics (TEGO) and a Master of Science in Gynecology & Obstetrics from the University of Sao Paulo. His educational achievements culminated in an MBA in Strategic Management from Fundação Getúlio Vargas in collaboration with Ohio University, where he earned the Best Student Award.
Experience 💼
Marcelo has accumulated diverse experience in the pharmaceutical industry, notably as the Global Women’s Health Medical Lead at Abbott, where he spearheaded groundbreaking initiatives in Menopause treatment and reproductive health. His previous roles include Onco-Hematology Medical Lead at AstraZeneca and positions at Eurofarma and Merck Serono, focusing on therapeutic portfolio management and strategic medical affairs.
Research Interest 🧬
His research interests span the spectrum of Women’s Health, Oncology, and clinical data generation, emphasizing safety and efficacy in hormonal therapies, endometriosis, and other gynecological disorders. Marcelo actively contributes to scientific advancements through collaboration with global medical societies and continuous medical education programs.
Award 🏆
Marcelo Graziano Custodio has been recognized with numerous awards, including Abbott’s Excellence Awards for his leadership and scientific contributions in Women’s Health, Menopause treatment, and evidence-based medicine. His accolades underscore his commitment to innovation and medical excellence.
Publication 📄
Publication: Teich V, Custodio MG, Laloni MT, Costa MADSB, Campolina AG, Holtz L, Oliveira M, Bortoleto N, Salgado J. A Multicriteria Decision Analysis (MCDA) to Evaluate Alternative Treatments for Locally Advanced or Metastatic EGFR Positive Non-Small Cell Lung Cancer under the Brazilian Private Healthcare System Perspective. Value in Health. 2019; 22(Suppl 2): S98.
Publication: Ferreira CG, Custodio M, Montenegro G, Caetano R, Bonan L. Economic Evaluation of Diagnostic Platforms for T790M Detection in Post EGFR-TKI NSCLC in Brazil. Journal of Thoracic Oncology. October 2018; 13(10): S676–S677.
Publication: Ferreira CG, Zallis M, Zukin M, Castro Jr. G, Mathias C, Haddad CK, de Lima VCC, Araújo LH, Baldotto C, Gelatti A, Bustamante C, Custodio MG, Montenegro GT, de Souza AG, Reis M. Updated EGFR Mutation Frequency in 1,689 NSCLC Brazilian Patients – A National-Wide Study. Journal of Thoracic Oncology. October 2018; 13(10): S676.
Publication: Cronemberger E, Baldotto C, Marinho F, De Marchi P, Araújo LH, Franke F, Salles P, Calabrich A, Almeida T, Custodio MG, Araujo C, Horacio M, Castro Jr G. EGFR Mutation and Targeted Therapies: Difficulties and Disparities in Access to NSCLC Treatment in Brazil. Journal of Thoracic Oncology. October 2018; 13(10): S871–S872.
Publication: Araújo LH, Castro Jr G, De Marchi P, Baldotto C, Werutsky G, Borges G, Mathias C, Calabrich A, Costa C, Franke F, Lima E, Neron Y, Schwartsmann G, Custodio MG, Sansevero C, Freitas HC. Efficacy and Safety of Osimertinib After Prior EGFR TKI: Analysis of Patients Underrepresented in Randomized Clinical Trials. Journal of Thoracic Oncology. October 2018; 13(10): S801.